Growth Metrics

Novavax (NVAX) Operating Leases (2020 - 2024)

Historic Operating Leases for Novavax (NVAX) over the last 5 years, with Q4 2024 value amounting to $76.7 million.

  • Novavax's Operating Leases fell 924.97% to $76.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $76.7 million, marking a year-over-year decrease of 924.97%. This contributed to the annual value of $76.7 million for FY2024, which is 924.97% down from last year.
  • According to the latest figures from Q4 2024, Novavax's Operating Leases is $76.7 million, which was down 924.97% from $84.5 million recorded in Q4 2023.
  • In the past 5 years, Novavax's Operating Leases registered a high of $84.5 million during Q4 2023, and its lowest value of $39.1 million during Q4 2021.
  • Moreover, its 5-year median value for Operating Leases was $76.7 million (2024), whereas its average is $66.4 million.
  • Its Operating Leases has fluctuated over the past 5 years, first crashed by 2208.74% in 2021, then skyrocketed by 10790.21% in 2022.
  • Quarter analysis of 5 years shows Novavax's Operating Leases stood at $50.2 million in 2020, then decreased by 22.09% to $39.1 million in 2021, then soared by 107.9% to $81.3 million in 2022, then rose by 3.91% to $84.5 million in 2023, then fell by 9.25% to $76.7 million in 2024.
  • Its Operating Leases was $76.7 million in Q4 2024, compared to $84.5 million in Q4 2023 and $81.3 million in Q4 2022.